



# aTyr Pharma

## **aTyr Pharma to Present at 15th Annual Needham & Company Healthcare Conference**

April 6, 2016

SAN DIEGO, April 6, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the 15th Annual Needham & Company Healthcare Conference to be held at The Westin Grand Central Hotel in New York City from April 12-13, 2016.



## aTyr Pharma

John Mendlein, Ph.D., aTyr's Chief Executive Officer, will provide an overview of the Company during a presentation at 8:40 AM a.m. ET on Wednesday, April 13, 2016. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at [www.atyrpharma.com](http://www.atyrpharma.com), and presentation slides will also be made available for download. An audio replay will be available for 30 days following the initial presentation webcast.

### **About aTyr Pharma**

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris<sup>TM</sup>, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathy) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. To protect this pipeline, aTyr built an intellectual property estate comprising over 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit <http://www.atyrpharma.com>.

### **Contact:**

**Sanuj K. Ravindran, MD**     **Jesse Baumgartner**

Chief Business Officer             Stern Investor Relations, Inc.

[sravindran@atyrpharma.com](mailto:sravindran@atyrpharma.com)     [jesse@sternir.com](mailto:jesse@sternir.com)

858-223-1163                     212-362-1200

Logo - <http://photos.prnewswire.com/prnh/20120809/MM55538LOGO>

SOURCE aTyr Pharma, Inc.